Mariner
NAUT icon

Mariner’s Nautilus Biotechnolgy NAUT Stock Holding History

Mariner’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,863
Closed -$73K – 2980
2023
Q2 		$73K Sell
18,863
-126
-0.7% -$363 ﹤0.01% 2677
2023
Q1 		$53K Buy
18,989
+1,012
+6% +$2.12K ﹤0.01% 2655
2022
Q4 		$32K Buy
+17,977
New +$34.7K ﹤0.01% 2655

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Mariner's NAUT Position: Q3 2023 in Review

Mariner sold out of Nautilus Biotechnolgy (NAUT) in Q3 2023, closing a stake of 18,863 shares — an estimated $73K sold.

Mariner first reported a position in NAUT in Q4 2022 and held it in 3 quarters. The position peaked at $73K in Q2 2023. 75 funds tracked by Wall St. Rank hold NAUT as of Q3 2023.

  • Mariner reported no remaining Nautilus Biotechnolgy position as of Q3 2023 after selling out during the quarter.
  • Mariner sold 18,863 Nautilus Biotechnolgy shares in Q3 2023, an estimated $73K.
  • Mariner first reported a position in Nautilus Biotechnolgy in Q4 2022 and held it in 3 quarters.
  • Mariner's Nautilus Biotechnolgy position peaked at $73K in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2023.

Based on Mariner's 13F filing for Q3 2023, filed 13 Nov 2023.